Selumetinib bulk supplier for pharma manufacturers

Selumetinib 10mg, 25mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 10mg, 25mg

Reference Brands: Koselugo (USA)

Category: Neurology

Selumetinib is a selective inhibitor of the enzymes MEK1 and MEK2, which are part of a signalling pathway involved in cell growth and division. By blocking MEK1/2, selumetinib helps reduce abnormal growth of nerve-sheath tumors (plexiform neurofibromas) in people with genetic disorder Neurofibromatosis type 1 (NF1). Koselugo is indicated for patients (children and now adults) with symptomatic, inoperable plexiform neurofibromas — helping shrink tumor volume or slow growth when surgical removal is not feasible.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Selumetinib? List it or send an offer →

Product Description:

Selumetinib is an oral, selective inhibitor of MEK1 and MEK2, kinases downstream of RAS. In neurofibromatosis type 1, loss of the NF1 gene product removes a brake on RAS signalling, and plexiform neurofibromas grow along nerve sheaths — often large, disfiguring and painful, and frequently impossible to remove surgically. Inhibiting MEK blocks the signal that drives that growth, and in the pivotal paediatric trial most children had lasting tumour shrinkage together with improvements in pain and function.

It was approved first for children with symptomatic, inoperable plexiform neurofibromas, and in 2025 the US extended the indication to adults. It is taken twice daily on an empty stomach and dosed by body surface area. Adverse effects follow the MEK-inhibitor class: acneiform rash, paronychia, diarrhoea, raised creatine phosphokinase, reduced left ventricular ejection fraction and ocular toxicity, including retinal vein occlusion. Echocardiography and eye examinations are part of monitoring.

Sourcing notes. Originator product, on patent, no generic. Capsule strengths are small to support dosing by body surface area in children, and a granule formulation for younger patients has been developed in some markets. Registration and the adult indication vary by market and are still expanding. Supply is through authorised distribution or named-patient access.

How Selumetinib is supplied today, and licensing ahead of patent expiry

Selumetinib is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Selumetinib, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Selumetinib supply →

Back to Listing

Frequently Asked Questions

Selumetinib is used to treat neurofibromatosis type 1 (NF1) in children with inoperable plexiform neurofibromas. It works by inhibiting the MEK1 and MEK2 enzymes in the RAS/MAPK pathway, which helps reduce tumor growth.

Selumetinib is made from the active pharmaceutical ingredient selumetinib hydrochloride, a small-molecule MEK inhibitor.

The trade name is Koselugo.

Koselugo is manufactured by AstraZeneca.

The generic name is selumetinib hydrochloride.

The primary brand name is Koselugo.

It is manufactured in approved pharmaceutical facilities in Europe and the USA, depending on regulatory approvals.

Koselugo (Selumetinib) is developed and sold by AstraZeneca (Alexion), with Merck & Co. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.